- Home
- WYY vs CVKD Comparison
WYY vs CVKD Comparison
Compare WYY & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WYY
- CVKD
- Stock Information
- Founded
- WYY 1991
- CVKD 2022
- Country
- WYY United States
- CVKD United States
- Employees
- WYY N/A
- CVKD N/A
- Industry
- WYY EDP Services
- CVKD Medicinal Chemicals and Botanical Products
- Sector
- WYY Technology
- CVKD Health Care
- Exchange
- WYY Nasdaq
- CVKD Nasdaq
- Market Cap
- WYY 33.6M
- CVKD 29.5M
- IPO Year
- WYY 1998
- CVKD 2023
- Fundamental
- Price
- WYY $3.19
- CVKD $12.68
- Analyst Decision
- WYY Strong Buy
- CVKD Strong Buy
- Analyst Count
- WYY 1
- CVKD 1
- Target Price
- WYY $7.00
- CVKD $32.00
- AVG Volume (30 Days)
- WYY 81.2K
- CVKD 33.5K
- Earning Date
- WYY 08-13-2025
- CVKD 08-06-2025
- Dividend Yield
- WYY N/A
- CVKD N/A
- EPS Growth
- WYY N/A
- CVKD N/A
- EPS
- WYY N/A
- CVKD N/A
- Revenue
- WYY $142,582,209.00
- CVKD N/A
- Revenue This Year
- WYY $10.84
- CVKD N/A
- Revenue Next Year
- WYY $12.37
- CVKD N/A
- P/E Ratio
- WYY N/A
- CVKD N/A
- Revenue Growth
- WYY 24.03
- CVKD N/A
- 52 Week Low
- WYY $2.19
- CVKD $5.70
- 52 Week High
- WYY $6.25
- CVKD $22.90
- Technical
- Relative Strength Index (RSI)
- WYY 43.21
- CVKD 47.47
- Support Level
- WYY $3.21
- CVKD $11.00
- Resistance Level
- WYY $3.46
- CVKD $13.24
- Average True Range (ATR)
- WYY 0.19
- CVKD 1.13
- MACD
- WYY 0.02
- CVKD 0.20
- Stochastic Oscillator
- WYY 32.14
- CVKD 72.33
About WYY WidePoint Corporation
WidePoint Corp is a provider of Technology Management as a Service (TMaaS) that consists of federally certified communications management, identity management, interactive bill presentment and analytics, and an Information Technology as a Service solution. Its solutions include Telecom Lifecycle Management, Digital billing communications solutions, and Mobile and Identity management. Geographically, the company generates a majority of its revenue from the United States and the rest from Europe.
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.